Original article

ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study

Rodolfo Patussi Correia\textsuperscript{a,b,*}, Flávia Amoroso Matos e Silva\textsuperscript{c}, Nydia Strachman Baca\textsuperscript{b,d}, Paulo Vidal Campregher\textsuperscript{a,b}, Nelson Hamerschlak\textsuperscript{a,b}, Gustavo Pessini Amarante-Mendes\textsuperscript{c,f}

\textsuperscript{a} Instituto Israelita de Ensino e Pesquisa, São Paulo, SP, Brazil
\textsuperscript{b} Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
\textsuperscript{c} Centro de Ciências Biomédicas, Universidade de São Paulo (ICB USP), São Paulo, SP, Brazil
\textsuperscript{d} Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
\textsuperscript{f} Instituto Nacional de Ciência e Tecnologia (INCT), Brazil

**ARTICLE INFO**

Article history:
Received 8 March 2017
Accepted 28 March 2018
Available online 11 June 2018

Keywords:
Chronic lymphocytic leukemia
ZAP-70 protein-tyrosine kinase
Memory T cells

**ABSTRACT**

Background: Although chronic lymphocytic leukemia is basically a B cell disease, its pathophysiology and evolution are thought to be significantly influenced by T cells, as these are probably the most important interaction partner of neoplastic B cells, participating in their expansion, differentiation and survival. Chronic lymphocytic leukemia B cells may also drive functional and phenotypic changes of non-malignant T cells. There are few data about the association between memory T cells and prognosis, especially related to ZAP-70, a common reliable surrogate of the gold standard chronic lymphocytic leukemia prognostic markers.

Objective: The aim of this study was to investigate whether the expression of ZAP-70 in chronic lymphocytic leukemia patients is associated with abnormal patterns of the distribution of naïve and memory T cells related to crosstalk between these cells.

Methods: In this cross-sectional, controlled study, patients with chronic lymphocytic leukemia were compared with healthy blood donors regarding the expression of ZAP-70 and the distribution of naïve and memory T cell subsets in peripheral blood as measured by flow cytometry.

Results: ZAP-70 positive patients presented an increased frequency and absolute number of central memory CD4\textsuperscript{+} T cells, but not CD8\textsuperscript{+} T cells, compared to ZAP-70 negative patients and age-matched apparently healthy donors.

* Corresponding author at: Laboratory of Clinical Pathology, Flow Cytometry Division, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, Morumbi, São Paulo, SP, CEP: 05652-900, Brazil.
E-mail address: rodolfopic@gmail.com (R.P. Correia).

https://doi.org/10.1016/j.htct.2018.03.008
2531-1379/© 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative neoplasm in Western countries; it is characterized by an accumulation of mature CD5+ B cells in hematopoietic tissue due to the imbalance in the rates of proliferation and apoptosis. It has been reported that genetic predisposition, mutations, familial history, environmental factors and clonal evolution induced by antigens and/or auto-antigens are elements related to the etiology of the disease.1-3

The clinical course of CLL is heterogeneous and varies between individuals.1,4 Several clinical and laboratory data are considered prognostic markers, including Rai and Binet staging, lymphocyte count doubling time, cytogenetics, different genetic mutations, zeta-chain-associated protein kinase 70 (ZAP-70) expression and the Ig heavy chain V-III region VH26 (IgVH) gene mutational status.5,6,7,8 Of these, ZAP-70 expression, detected by flow cytometry, is commonly used as a reliable surrogate for gold standard prognostic markers.8

Although CLL is basically a B cell disease, it has been proposed that its pathophysiology and evolution are significantly influenced by T cells as they participate in their expansion, differentiation and survival, which may also influence T lymphocyte function and phenotype.9,10 with the accumulation of memory T cells in CLL patients.11,12 However there are few data about the association between memory T cells and the prognosis of CLL, especially related to ZAP-70.

Thus, this study analyzed the peripheral T cell compartment of CLL patients, to evaluate whether ZAP-70 expression is associated with an abnormal distribution of naïve and memory T cells related to the crosstalk between these cells, and consequently to the prognosis of the disease.

Methods

Study design, ethics and setting

This controlled cross-sectional study compared CLL patients with healthy blood donors regarding the distribution of naïve and memory T-cell subsets in peripheral blood. The study was conducted in two referral centers for hematology and oncology in Brazil, one private and the other a public teaching institution.

All healthy blood donors and patients signed informed consent forms thereby agreeing to participate in this study. The review boards of both institutions reviewed and approved the study protocol.

Healthy donors and patients

The case group of this study were all adult patients admitted for the diagnosis of CLL from September 2011 to September 2012. The control group comprised blood donors from the same institutions during the same period.

A volume of approximately 10 mL of peripheral blood (PB) was collected from all participants in tubes with anticoagulant heparin or ethylenediaminetetraacetic acid (EDTA) for flow cytometry. In the blood banks, the sample was collected after voluntary donations.

Flow cytometry assay

The flow cytometry assay used in this study for the evaluation of the ZAP-70 expression was performed in the Flow Cytometry Laboratory of the Clinical Pathology Laboratory of Hospital Israelita Albert Einstein. The technical procedures and flow cytometry settings followed standard operating procedures (SOP) previously validated in the laboratory and the quality was monitored by internal and external quality controls as published by the American College of Pathology (CAP) and United Kingdom National External Quality Assessment Service (UKNEQAS).

The expression of ZAP-70 in B-cell CLL patients was always evaluated in parallel to a sample of peripheral blood from a healthy donor in order to validate the intracytoplasmic reaction and the ZAP-70 antigenic expression in T-cells (positive) and B cells (negative).

All fluorochrome-conjugated antibodies were validated before use according to the reaction specificity and the best volume capable of providing the antigen–antibody binding saturation (titration).

Characterization of naïve and memory T cells

Peripheral blood mononuclear cells (PBMC) from healthy donors and CLL patients were obtained and purified using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Sweden) and density gradient centrifugation.13

The cell concentration and viability were assessed using an optical microscope, Neubauer chamber and trypan blue. An aliquot of 1 x 10⁶ cells were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD45RA, anti-CD62L monoclonal antibodies (mAbs) conjugated with peridinin chlorophyll protein (PerCP), allophycocyanin cyanine 7 (APC-Cy7), phycoerythrin cyanine 7 (PE-Cy7), fluorescein isothiocyanate (FITC) and phycoerythrin (PE), respectively (Becton, Dickinson San Jose, CA, USA).
After incubation and washing, samples were analyzed by flow cytometry in a BDFACS Canto II apparatus (Becton, Dickinson, San Jose, CA, USA) using the FlowJo software – (Tree Star, Inc.).

CD4+ and CD8+ T cells were respectively determined by double positivity of CD3+CD4+ and CD3+CD8+. Moreover, CD45RA and CD62L expressions were used to identify naïve T cells (CD45RA+CD62L+), central memory T cells (TEM; CD45RA−CD62L−), effector memory T cells (CD45RA−CD62L−) and terminal effector memory T cells (CD45RA−CD62L−) (Figure 1). This strategy was used for both healthy donors and CLL patients.

**ZAP-70 expression in CLL patients**

For the ZAP-70 flow cytometry assay, $5 \times 10^6$ PB cells from healthy donors and CLL patients were stained with anti-CD3 and anti-CD19 mAbs and conjugated with phycoerythrin cyanine (PE-Cy5) and PE, respectively (Beckman Coulter). For cytoplasmic staining, cells were fixed, permeabilized and stained with anti-ZAP-70 mAb conjugated with AlexaFluor488 (clone 1E7.2, Invitrogen). Samples were analyzed in a Cytomics FC500 apparatus (Beckman Coulter – Figure 2).

The cut-off for ZAP-70 positivity was based on published data, which recommends positivity when more than 20% of neoplastic B lymphocytes express ZAP-70.8

To standardize the technique, the ZAP-70 expression was always analyzed in the samples of healthy donors in parallel to CLL patients. Furthermore, the isotype control for AlexaFluor488 was used as a negative control of the reaction, while the expression of ZAP-70 on normal T lymphocytes was considered the positive control.14

**Statistical analysis**

The normal distribution of the data was tested using the Kolmogorov–Smirnov test for each type of cell and there was no statistical significance to reject the assumption of normality. The comparison between cell types in total was performed...
using the paired Student t-test and the comparison between the cell subpopulations was performed using repeated measures analysis of variance (ANOVA) followed by Bonferroni multiple comparison. Comparison between groups (healthy and case) and cell types or subtypes were achieved using two-way ANOVA followed by Bonferroni multiple comparison when necessary. Statistical differences were considered significant when p-values were <0.05.

Results

In the study period, 21 CLL patients and 43 controls were enrolled. In the control group, 17 patients were over 40 years old. Table 1 summarizes the characteristics of the control group and the clinical and laboratory data of the CLL patients are summarized in Table 2.

**Distribution profile of naïve and memory T cells**

As expected, the frequency and the absolute number of CD4+ T cells were higher than those of CD8+ T cells in the Control Group (Figure 3). The T cell compartment was also characterized and the CD4 and CD8 subpopulations had different distributions according to memory T cell subsets. Central memory T cells (T_{CM}) were predominant in the CD4+ T cell compartment, whereas T_{CM} were fewer of the CD8+ T lymphocytes with T_{EM} and T_{EMRA} being distributed equally among CD8+ T lymphocytes (Figure 3C and D).

**Characterization of T cell compartment in chronic lymphocytic leukemia patients**

The analysis of the T cell compartment in CLL patients showed that, due to the increased numbers of neoplastic B lymphocytes in PB, the frequencies of CD4+ and CD8+ T lymphocytes were extremely low compared to healthy donors (Figure 4). Similar absolute numbers were observed in the PB of both patients and healthy controls (Figure 4).
**Figure 3** – Distribution profile of T cells in healthy donors. (A) Frequency and (B) absolute number of peripheral blood CD4+ and CD8+ T cells from healthy individuals as assessed by flow cytometry. Frequency of memory (C) CD4+ and (D) CD8+ T cell subpopulations according to the CD45 and CD62L expression [central memory T cells (TCM = CD45RA− CD62L+), effector memory T cells (TEM = CD45RA− CD62L−) and terminal effector memory T cells (TEMRA = CD45RA+ CD62L−)]. The values were statistically significant with p-value < 0.001 (***) and p-value = 0.003 (**).

**Figure 4** – Absolute number of CD4 and CD8 T cells is not changed in chronic lymphocyte leukemia (CLL) patients. (A) Frequency of peripheral blood CD4+ and CD8+ T cells in CLL patients compared to healthy donors. The values were statistically significant with p-value < 0.001 (***) (B) Absolute number of peripheral blood CD4+ and CD8+ T cells from CLL patients compared to the healthy donors.

*Distribution pattern of naïve and memory T cells in chronic lymphocytic leukemia patients*

No differences in the frequency and the absolute number of naïve, TCM, TEM and TEMRA were observed in the CD4+ and CD8+ T cell populations (**Figure 5**). However, ZAP-70 positive patients had significant differences in the frequencies of naïve and absolute number of TCM in the CD4+ T cell compartment. There was no difference in the frequency or the absolute number of CD8+ T cells in CLL patients compared to age-matched apparently healthy individuals (**Figure 6**).

*Age-dependent differences in the distribution of naïve and memory T cells*

The literature suggests that events related to the age, such as homeostatic regulation, thymus involution and antigenic stimulation could affect the naïve and memory T cell
Figure 5 – Naïve and memory T cell distributions in chronic lymphocyte leukemia (CLL) patients. Peripheral blood T cell subsets in CLL patients and age-matched healthy donors (Group 2) were determined by flow cytometry. (A) Frequency and (B) absolute number of CD4+ naïve and memory T cells subsets. (C) Frequency and (D) absolute number of CD8+ naïve and memory T cells subsets. T<sub>CM</sub>: central memory T cells; T<sub>EM</sub>: effector memory T cells; T<sub>EMRA</sub>: terminal effector memory T cells.

Figure 6 – Naïve and memory CD4+ T cell distributions are related to the ZAP-70 expression in chronic lymphocyte leukemia (CLL) patients. (A–C) Frequency and (B–D) absolute number of CD4+ and CD8+ naïve and memory T cells subsets in CLL patients with and without ZAP-70 expression in comparison to age-matched healthy donors. Differences in the frequencies of naïve and absolute number of central memory T cells in the CD4+ T cell compartment were statistically significant with p-value < 0.001 and p-value = 0.008, respectively. T<sub>CM</sub>: central memory T cells; T<sub>EM</sub>: effector memory T cells; T<sub>EMRA</sub>: terminal effector memory T cells.
Figure 7 – Distribution of naïve and memory subtypes of CD8⁺ T cells, but not CD4⁺ T cells, is age dependent. Analysis of the frequency distribution of (A–D) CD4⁺ and (E–F) CD8⁺ naïve, central memory T cells (T_{CM}), effector memory T cells (T_{EM}) and terminal effector memory T cells (T_{EMRA}) in healthy donors (19–72 years old). Linear regression was used to evaluate the changes.
Therefore, the next step was to rule out the possibility that the increase in T_{CM} CD4^+ cells was due to differences in the ages of the patients. On analyzing the healthy group (19–72 years old), no differences were observed in the naïve and memory CD4^+ T cells with age (Figure 7), but in the CD8^+ T cell compartment, the naïve T cells diminished and T_{CM} and T_{EMRA} cells increased with age (Figures 7E–H).

### Discussion

The involvement of T cells in the pathophysiology of hemato logic malignancies, especially in CLL, is widely discussed. The interaction of neoplastic B cells with their microenvironment, particularly CD4^+ T lymphocytes and with extracellular components, could regulate the expansion, differentiation, and survival of neoplastic B cells, and possibly influence the T lymphocyte gene expression, function and phenotype.\(^5\,10\) This study showed that ZAP-70 positive patients presented increased T_{CM} CD4^+ T cells compared to ZAP-70 negative patients and to age-matched healthy donors (Figure 5).

Memory T cells represent a heterogeneous group of cells characterized by their phenotypic diversity, proliferative index versus effector function, and migratory capability to lymph nodes and/or to peripheral tissues. They are classified into three major groups: T_{CM}, T_{EM}, and T_{EMRA}. Briefly, T_{CM} are located in lymph nodes and have low effector function with a high proliferative index. On the other hand, T_{EM} and T_{EMRA} are characterized by high effector function in the liver, lung, and gut and with a low proliferative index. Together, these cells provide immediate protection in peripheral tissues and efficient secondary response in lymph nodes.\(^15\,18\)

It is well established that the signaling and antigenic stimulation by B cell receptors (BCRs) is crucial for survival and growth of CLL cells, even though it is a disease with a low proliferative index.\(^19\) In this context, T_{CM} CD4^+ cells can migrate to the lymph nodes due to the expression of CD62L and CCR7, and interact with B cells by CD40L and CXCR5, that consequently could contribute to stronger BCR signaling, expansion and evolution of the disease.\(^18\) These data could support the finding that ZAP-70 positive CLL patients have increased T_{CM} CD4^+ T cells.

In addition to the modulation of BCR signaling, the cytokines produced by memory T cells, especially interleukin (IL)-4 and interferon-gamma (IFN-γ), could promote increased survival of the CLL clone.\(^20\,21\) Recently, a study showed that ZAP-70 expression in CLL is associated with a reduction of naïve CD4^+ T cells and increases in activation/differentiation of CD4^+ T cells to a memory profile that expresses IL-4 or IL-10. In addition, these cytokines might favor the growth and survival of CLL cells.\(^22\)

Furthermore, as neoplastic CLL B cells are inefficient as antigen presenting cells, the evidence that increased T_{CM} CD4^+ T cells could be a CLL mechanism is supported by the theory of the generation of memory T cells; a weak stimulation of naïve T cells during antigen presentation drives the differentiation of these cells into T_{CM} cells.\(^23\,24\)

To ratify that the changes detected in the CD4^+ memory T cell compartment are a CLL intrinsic mechanism and not an age-dependent event, the frequency of these cells was evaluated in healthy donors stratified by age. Indeed, events related to age, such as homeostatic regulation, thymus involution and antigenic stimulation were observed,\(^6\) but this mechanism only affected the CD8^+ T cell compartment (Figure 7). Therefore, our finding of increased T_{CM} CD4 cells is a consistent result and directly associated with CLL, in particular, associated to ZAP-70 expression in this disease.

This study has limitations in evaluating the real association between the results with CLL prognosis, especially due to absent of experimental verification and correlation with other clinical and laboratory data. Still, we believe the increase in T_{CM} CD4^+ T cells might be a result of the crosstalk mechanism between CLL ZAP-70 positive B cells with normal CD4^+ T cells, in which the neoplastic clone could obtain greater survival and expansion signals due to cytokines and costimulatory signals as described above. Interestingly, it is reported that murine models using animals deficient in B cells have impaired generation of CD4^+ memory T cells.\(^15\,25\)

These findings could be important to understand the pathophysiology, and consequently, they could help drive further investigations in the prognosis and treatment of CLL.

### Conflicts of interest

The authors declare no conflicts of interest.
REFERENCES

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri AS, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.

2. Inamdar RV, Bueso-Ramos CE. Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol. 2007;11(5):363–89.

3. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez CR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukemia. Nature. 2011;475(7354):101–5.

4. Riches JC, Ramsay AG, Gribben JG. Chronic lymphocytic leukemia: an update on biology and treatment. Curr Oncol Rep. 2011;13(5):379–85.

5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Fastenack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34.

6. Binet J, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.

7. Damle RN, Wilas T, Fais F, Ghio F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–7.

8. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764–75.

9. Correia RP, Mato E, Silva FA, Bacal NS, Campregher PV, Hamerschlak N, et al. Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia. Rev Bras Hematol Hemoter. 2014;36(1):60–4.

10. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(3):383–9.

11. Thimhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother. 2009;32(3):302–9.

12. Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25(9):1452–8.

13. Büyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1g. Scand J Clin Lab Invest Suppl. 1968;97:77–89.

14. Villamor N. ZAP-70 staining in chronic lymphocytic leukemia. Curr Protoc Cytom. 2005;6:19. Chapter 6:Unit 6 19.

15. Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity. 2009;31(6):659–71.

16. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol. 2011;12(6):467–71.

17. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63.

18. Sallusto F, Lenn D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–12.

19. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389–95.

20. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993;177(1):213–8.

21. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1993;85(3):439–45.

22. Monserrat J, Sánchez MÁ, de Paz R, Díaz D, Mur S, Reyes E, et al. Distinctive patterns of naive/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. Cytom B Clin Cytom. 2014;86(1):32–43.

23. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol. 2005;17(3):326–32.

24. Dazzi F, D’Andrea E, Biasi G, de Silvestro G, Gaidano G, Schena M, et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol. 1995;75(1):26–32.

25. Whitmire JK, Asano MS, Kao SM, Sarkar S, Hannum LG, Shlomchik MJ, et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol. 2009;182(4):1868–76.